

Nick Pavlakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3227622/publications.pdf>

Version: 2024-02-01

151
papers

4,815
citations

159585

30
h-index

110387

64
g-index

153
all docs

153
docs citations

153
times ranked

7908
citing authors

#	ARTICLE	IF	CITATIONS
1	Computed tomography (CT)-defined sarcopenia and myosteatorosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2022, 76, 143-149.	2.9	8
2	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	1.1	6
3	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 39-51.	2.4	0
4	Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	1
5	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366.	1.6	2
6	Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3387-3389.	1.5	1
7	Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 526-539.	1.1	4
8	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. <i>Targeted Oncology</i> , 2022, 17, 95.	3.6	2
9	An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma. <i>Lung Cancer: Targets and Therapy</i> , 2022, Volume 13, 1-12.	2.7	7
10	PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).. <i>Journal of Clinical Oncology</i> , 2022, 40, 12020-12020.	1.6	0
11	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284.	5.0	25
12	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 704-715.	4.1	10
13	Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	0
14	The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. <i>Patient Education and Counseling</i> , 2021, 105, 212-220.	2.2	1
15	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192.	2.4	3
16	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e859-e869.	2.6	23
17	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	2.0	18
18	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35

#	ARTICLE	IF	CITATIONS
19	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2700.	2.4	5
20	Immunotherapy in Non-“Small-Cell Lung Cancer: Hallelujah!” But Salvation Is Still Awaited by Many. <i>JCO Oncology Practice</i> , 2021, 17, OP.21.00506.	2.9	0
21	Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. <i>Immunotherapy</i> , 2021, 13, 941-952.	2.0	14
22	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021, 13, 4824.	3.7	29
23	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021, 11, 706331.	2.8	15
24	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	1.0	8
25	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021, 45, 394-404.	3.7	15
26	Life-threatening diarrhea in neuroendocrine tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 542.	0.8	2
27	341...A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). , 2021, 9, A367-A367.		0
28	340...A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC). , 2021, 9, A366-A366.		0
29	High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 950-958.	2.5	19
30	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	4.5	18
31	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223.	10.7	109
32	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555.	1.7	8
33	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 467-482.	2.9	56
34	Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?. <i>Cancers</i> , 2020, 12, 1341.	3.7	34
35	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	3.7	8
36	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 224-229.	1.1	9
38	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	2.4	4
39	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 305-324.	2.4	0
40	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positronâ€emission tomography positive intermediate grade pancreatic neuroendocrine tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 150-157.	1.1	2
41	The Economic Impact on Australian Patients with Neuroendocrine Tumours. <i>Patient</i> , 2020, 13, 363-373.	2.7	11
42	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	7.7	61
43	Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1539-1542.	1.0	6
44	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	2.0	27
45	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-12.	1.1	1
46	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075.	1.1	8
47	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646.	1.8	8
48	As cancer therapy becomes more complex, we must enhance our professional standards. <i>Journal of Pharmacy Practice and Research</i> , 2020, 50, 461-465.	0.8	0
49	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	10.7	117
50	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87.	2.0	29
51	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. <i>Pathology</i> , 2019, 51, 673-680.	0.6	8
52	Mass Cytometry Reveals a Sustained Reduction in CD16+ Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2584.	4.8	9
53	Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. <i>Journal of Clinical Medicine</i> , 2019, 8, 1455.	2.4	4
54	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	2.8	69

#	ARTICLE	IF	CITATIONS
55	Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 620.	3.7	9
56	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	1.1	324
57	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	2.4	10
58	Targeting BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 1119-1124.	2.8	65
59	Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1102-e1107.	3.7	9
60	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 218-224.	1.0	22
61	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. <i>JMIR Research Protocols</i> , 2019, 8, e14361.	1.0	3
62	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018, 14, 647-663.	2.4	23
63	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 339-349.	2.4	6
64	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	1.1	6
65	Convergent priorities and tensions: a qualitative study of the integration of complementary and alternative therapies with conventional cancer treatment. <i>Supportive Care in Cancer</i> , 2018, 26, 1791-1797.	2.2	8
66	Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). <i>Neuroendocrinology</i> , 2018, 107, 32-41.	2.5	10
67	Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. <i>Cancer Treatment Reviews</i> , 2018, 66, 1-6.	7.7	26
68	Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e45-e49.	1.1	3
69	Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. <i>ANZ Journal of Surgery</i> , 2018, 88, E167-E172.	0.7	16
70	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 256-263.	1.1	8
71	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018, 17, 458-466.	2.0	9
72	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	1.6	381

#	ARTICLE	IF	CITATIONS
73	EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS. <i>Neuro-Oncology</i> , 2018, 20, vi82-vi83.	1.2	2
74	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	3.2	19
75	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1784-1791.	1.1	75
76	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018, 29, 757-769.	2.2	12
77	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597.	7.1	68
78	Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 51.	1.4	6
79	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	2.4	44
80	Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. <i>Journal of Surgical Research</i> , 2018, 227, 158-167.	1.6	8
81	ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses. <i>Clinical Lung Cancer</i> , 2018, 19, 457-459.	2.6	8
82	Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0191455.	2.5	18
83	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	2.3	9
84	Factors Affecting Whether Or Not Cancer Patients Consider Using Acupuncture. <i>Acupuncture in Medicine</i> , 2017, 35, 107-113.	1.0	10
85	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	4.0	18
86	Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. <i>EJNMMI Research</i> , 2017, 7, 46.	2.5	45
87	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282.	4.4	42
88	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1386-1396.	10.7	508
89	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	2.3	33
90	Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. <i>Clinical Therapeutics</i> , 2017, 39, 2158-2168.	2.5	38

#	ARTICLE	IF	CITATIONS
91	Lost in translation: returning germline genetic results in genome-scale cancer research. <i>Genome Medicine</i> , 2017, 9, 41.	8.2	27
92	Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. <i>Journal of Global Oncology</i> , 2017, 3, 380-388.	0.5	6
93	Screening for <i>ROS1</i> gene rearrangements in non-small cell lung cancers using immunohistochemistry with <i>FISH</i> confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017, 70, 402-411.	2.9	52
94	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017, 7, 1149-1158.	10.0	201
95	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172307.	2.5	11
96	The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 29-29.	3.0	3
97	Clinical utilization of targetable molecular results in pancreatic cancer: Longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 314-314.	1.6	0
98	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre. <i>Journal of Clinical Oncology</i> , 2017, 35, 395-395.	1.6	0
99	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016, 11, e0158140.	2.5	22
100	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016, 8, 1079-1085.	2.1	176
101	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the <i>KRAS</i> G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
102	Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. <i>Neoplasia</i> , 2016, 18, 425-435.	5.3	30
103	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	2.0	11
104	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> and <i>PI3KCA</i> wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	2.6	15
105	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	1.6	183
106	Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3699-3708.	1.5	4
107	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016, 114, 524-531.	6.4	20
108	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> , 2016, 114, 505-509.	6.4	43

#	ARTICLE	IF	CITATIONS
109	Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. Journal of Clinical Oncology, 2016, 34, TPS9105-TPS9105.	1.6	6
110	Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 330-330.	1.6	0
111	Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (United States), 2015, 94, e1281.	1.0	56
112	Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. Journal of Clinical Medicine, 2015, 4, 75-84.	2.4	14
113	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE, 2015, 10, e0135599.	2.5	22
114	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Molecular and Clinical Oncology, 2015, 3, 817-819.	1.0	10
115	Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. Oxford Medical Case Reports, 2015, 2015, 194-195.	0.4	0
116	Localized malignant pleural mesothelioma with renal metastasis. Oxford Medical Case Reports, 2015, 2015, 170-172.	0.4	11
117	Equivocal ALK fluorescence in situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 2015, 67, 654-663.	2.9	15
118	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	1.6	280
119	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 2015, 21, 2029-2037.	7.0	209
120	HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer, 2015, 90, 617-619.	2.0	34
121	Preliminary direct evidence of a dose-response relationship for [Y-90]-microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy.. Journal of Clinical Oncology, 2015, 33, 11064-11064.	1.6	1
122	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) – Final overall and subgroup results.. Journal of Clinical Oncology, 2015, 33, 4003-4003.	1.6	11
123	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, e15111-e15111.	1.6	1
124	Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures of response and prognosis in patients treated with Y-90 microsphere selective internal radionuclide therapy (SIRT).. Journal of Clinical Oncology, 2015, 33, e22137-e22137.	1.6	0
125	Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System. Asia Oceania Journal of Nuclear Medicine and Biology, 2015, 3, 107-15.	0.1	10
126	Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. Journal of Clinical Medicine, 2014, 3, 1-24.	2.4	51

#	ARTICLE	IF	CITATIONS
127	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. Oxford Medical Case Reports, 2014, 2014, 105-106.	0.4	0
128	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 2014, 4, 6152.	3.3	20
129	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. Journal of Clinical Oncology, 2014, 32, 3552-3552.	1.6	2
130	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	1.6	1
131	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 534-534.	1.6	1
132	A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 547-547.	1.6	0
133	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. Journal of Clinical Oncology, 2014, 32, 438-438.	1.6	0
134	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 44-44.	1.6	0
135	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2014, 32, 7586-7586.	1.6	0
136	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 2013, 81, 422-427.	2.0	51
137	Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer.. Journal of Clinical Oncology, 2013, 31, 4081-4081.	1.6	3
138	The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, e22175-e22175.	1.6	1
139	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. Journal of Clinical Oncology, 2013, 31, TPS3649-TPS3649.	1.6	2
140	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157.	1.6	3
141	Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. World Journal of Oncology, 2013, 4, 74-82.	1.5	8
142	Bisphosphonates and other bone agents for breast cancer. , 2012, , CD003474.		98
143	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Supportive Care in Cancer, 2012, 20, 1235-1242.	2.2	179
144	BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.. Journal of Clinical Oncology, 2012, 30, 3515-3515.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. Journal of Clinical Oncology, 2012, 30, 7079-7079.	1.6	0
146	Phase III trials of neoâ€œadjuvant chemotherapy in Stage IIIA nonâ€œsmall cell lung cancer â€œ does size matter?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 73-75.	1.1	0
147	Cardiac toxicity from sunitinib: Do we need to be more vigilant?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 217-218.	1.1	1
148	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 167-176.	1.1	14
149	Ranpirnase â€œ an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opinion on Biological Therapy, 2006, 6, 391-399.	3.1	60
150	Anti-angiogenic therapy for lung cancer. The Cochrane Library, 0, , .	2.8	0
151	Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. The Cochrane Library, 0, , .	2.8	0